Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
一线抗逆转录病毒疗法失败的尼日利亚儿童获得了艾滋病毒耐药性:对二线多替拉韦使用的影响
基本信息
- 批准号:10326999
- 负责人:
- 金额:$ 18.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-07 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:15 year oldAddressAdultAdvisory CommitteesAfricaAge-MonthsBiological AssayCaringCategoriesChildChildhoodClinicalCountryDataDatabasesDoseDrug resistanceDrug usageEssential DrugsEvaluationFailureFutureGenotypeGoalsGuidelinesHIVHIV drug resistanceHIV-1HomeInfantIntegraseInternationalKnowledgeLamivudineLogistic RegressionsLopinavir/RitonavirLow incomeMethodsModelingNigeriaNigerianNucleosidesOutcomePatientsPopulationPositioning AttributeProtease InhibitorPublic HealthRegimenReportingResistanceReverse Transcriptase InhibitorsRiskSamplingSensitivity and SpecificitySiteSurveysTestingTimeVertebral columnViral load measurementVulnerable PopulationsWorld Health Organizationabacaviracquired drug resistanceantiretroviral therapybasedesigndetection testhigh riskimprovedimproved outcomenext generationnon-nucleoside reverse transcriptase inhibitorsnovelpoint of carepoint of care testingpreventresistance mutationscale upsuccessvirology
项目摘要
PROJECT SUMMARY
The accumulation of HIV drug resistance (HIVDR) threatens to erode gains in HIV treatment globally. As a
result, the World Health Organization (WHO) Global Action Plan on HIVDR has called for increased
surveillance. Notably, the 2019 WHO Drug Resistance report included data on the alarming increase in
pretreatment HIV drug resistance (PDR) among adults and infants, as well as data on acquired drug
resistance (ADR) among adults failing first-line ART. However, data on ADR among children is glaringly
absent.
As countries begin to implement 2019 WHO guidance to replace lopinavir/ritonavir- with dolutegravir (DTG)-
based second-line ART among children, data on ADR is even more pertinent. While DTG holds great
promise for improving HIV outcomes and reducing drug resistance given its potency and high barrier to
resistance, its use for second-line ART among patients with pre-existing nucleoside reverse transcriptase
inhibitor (NRTI) resistance is unknown. Failed studies of DTG monotherapy provide a cautionary message
that the NRTI backbone remains important for virologic suppression and preventing integrase resistance.
Nigeria is home to more children living with HIV than any other country in the world. In a national survey of
PDR among ART-naïve infants ≤18 months of age, high rates of resistance were observed, including to the
most widely used NRTI backbone among children (abacavir and lamivudine). However, rates of ADR after
first-line failure are expected to be even higher. Since 2004, APIN Public Health Initiatives has provided HIV
care and treatment to over 20,000 children in Nigeria, and thus is uniquely positioned to provide critical drug
resistance data from multiple pediatric sites/regions across Nigeria. We propose to evaluate ADR among
400 children in Nigeria failing first-line ART, and will utilize these data to derive a clinical prediction rule
(CPR) to identify those most likely to benefit from targeted HIVDR testing and avoid functional DTG
monotherapy. Further, rapid point-of-care (POC) HIVDR testing is needed to address feasibility barriers in
low income settings. We will therefore evaluate the OLA-Simple POC HIVDR assay, which has equivalent
sensitivity to standard sequencing methods, but has not been validated among the unique HIV-1 subtypes
prevalent in Nigeria. This combination of studies addresses a critical gap in knowledge regarding ADR
among children failing first-line ART, will inform future studies of targeted HIVDR testing prior to second-line
switch, and will evaluate a rapid POC HIVDR assay in this setting. This has the potential to impact
international guidance on second-line DTG use and HIVDR testing for this vulnerable population of children.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Holly Elizabeth Rawizza其他文献
Holly Elizabeth Rawizza的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Holly Elizabeth Rawizza', 18)}}的其他基金
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
注意差距:推进儿科艾滋病毒/结核病联合治疗和结核病预防的药代动力学研究
- 批准号:
10390005 - 财政年份:2022
- 资助金额:
$ 18.03万 - 项目类别:
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
注意差距:推进儿科艾滋病毒/结核病联合治疗和结核病预防的药代动力学研究
- 批准号:
10605218 - 财政年份:2022
- 资助金额:
$ 18.03万 - 项目类别:
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
一线抗逆转录病毒疗法失败的尼日利亚儿童获得了艾滋病毒耐药性:对二线多替拉韦使用的影响
- 批准号:
10483175 - 财政年份:2021
- 资助金额:
$ 18.03万 - 项目类别:
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children
优化儿童艾滋病毒/结核病联合治疗方案的药代动力学和规划评估
- 批准号:
10422433 - 财政年份:2021
- 资助金额:
$ 18.03万 - 项目类别:
Rifabutin pharmacokinetics and safety among HIV/TB coinfected infants receiving lopinavir
接受洛匹那韦治疗的 HIV/TB 合并感染婴儿中利福布汀的药代动力学和安全性
- 批准号:
9926695 - 财政年份:2020
- 资助金额:
$ 18.03万 - 项目类别:
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children
优化儿童艾滋病毒/结核病联合治疗方案的药代动力学和规划评估
- 批准号:
9140789 - 财政年份:2016
- 资助金额:
$ 18.03万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.03万 - 项目类别:
Research Grant